1. ALLA AKTIER
  2. NYHETER
  3. XBRANE BIOPHARMA

Xbrane Biopharma

Nyheter Xbrane Biopharma Nyheter alla bolag

Xbrane Biopharma AB ("Xbrane" or the "Company") announces changes to the number of shares and votes in the Company.

LHFI

The number of shares and votes in Xbrane have changed following the issue of 79,252 shares during October through exercise of warrants under LTIP 2020, adopted at the annual general meeting 2020.

As of October 31, 2023, the total number of shares and votes in the Company amounts to 29,810,364. The Company's registered share capital amounts to about SEK 6,683,068.

Contacts

Martin Åmark, CEO
M: +46 76 309 37 77
E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR
M: +46 76 325 60 90
E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 53 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during the first quarter 2023. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com  

This information is information that Xbrane Biopharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-10-31 13:00 CET.

Attachments

Xbrane Biopharma AB ("Xbrane" or the "Company") announces changes to the number of shares and votes in the Company.

Datum 2023-10-31, kl 13:00
Källa MFN
Bifogade filer
Xbrane Biopharma AB ("Xbrane" or the "Company") announces changes to the number of shares and votes in the Company.
Affiliate
Alla Aktier tipsar: Nu får du 200 kr gratis när du skapar konto på Nordnet, insatt i fonden Nordnet One Balanserad. Bra tillfälle för dig som inte kommit igång med investeringar än, eller bara testat t.ex. Avanza.
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet